Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Sep;34(9):1812–1813. doi: 10.1128/aac.34.9.1812

Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer.

K V Rolston 1, M Messer 1, D H Ho 1
PMCID: PMC171934  PMID: 2285297

Abstract

The in vitro susceptibilities of three Pseudomonas species (Pseudomonas aeruginosa, Pseudomonas putida, and Pseudomonas fluorescens) and Xanthomonas maltophilia to quinolone antimicrobial agents were determined. Several newer agents, particularly PD117558, PD117596, PD127391, sparfloxacin (AT-4140), A-56620, and temafloxacin, were active against Pseudomonas species. X. maltophilia isolates were generally less susceptible than were Pseudomonas isolates but were inhibited by some of the newer quinolones.

Full text

PDF
1812

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anaissie E., Fainstein V., Miller P., Kassamali H., Pitlik S., Bodey G. P., Rolston K. Pseudomonas putida. Newly recognized pathogen in patients with cancer. Am J Med. 1987 Jun;82(6):1191–1194. doi: 10.1016/0002-9343(87)90223-3. [DOI] [PubMed] [Google Scholar]
  2. Asahara M., Tsuji A., Goto S., Masuda K., Kiuchi A. In vitro and in vivo activities of QA-241, a new tricyclic quinolone derivative. Antimicrob Agents Chemother. 1989 Aug;33(8):1144–1152. doi: 10.1128/aac.33.8.1144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barry A. L., Thornsberry C., Jones R. N. In vitro evaluation of A-56619 and A-56620, two new quinolones. Antimicrob Agents Chemother. 1986 Jan;29(1):40–43. doi: 10.1128/aac.29.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bodey G. P., Jadeja L., Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med. 1985 Sep;145(9):1621–1629. doi: 10.1001/archinte.145.9.1621. [DOI] [PubMed] [Google Scholar]
  5. Karp J. E., Merz W. G., Hendricksen C., Laughon B., Redden T., Bamberger B. J., Bartlett J. G., Saral R., Burke P. J. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1987 Jan;106(1):1–7. doi: 10.7326/0003-4819-106-1-1. [DOI] [PubMed] [Google Scholar]
  6. King A., Boothman C., Phillips I. The in-vitro activity of PD127,391, a new quinolone. J Antimicrob Chemother. 1988 Aug;22(2):135–141. doi: 10.1093/jac/22.2.135. [DOI] [PubMed] [Google Scholar]
  7. Kumada T., Neu H. C. In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents. J Antimicrob Chemother. 1985 Nov;16(5):563–574. doi: 10.1093/jac/16.5.563. [DOI] [PubMed] [Google Scholar]
  8. Neu H. C., Chin N. X. In vitro activity of PD 117596-2, a broad-spectrum difluoroquinolone. Eur J Clin Microbiol Infect Dis. 1989 Jul;8(7):644–650. doi: 10.1007/BF01968149. [DOI] [PubMed] [Google Scholar]
  9. Neu H. C., Novelli A., Chin N. X. Comparative in vitro activity of a new quinolone, AM-1091. Antimicrob Agents Chemother. 1989 Jul;33(7):1036–1041. doi: 10.1128/aac.33.7.1036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rolston K. V., Anaissie E. A., Bodey G. P. In-vitro susceptibility of Pseudomonas species to fifteen antimicrobial agents. J Antimicrob Chemother. 1987 Feb;19(2):193–196. doi: 10.1093/jac/19.2.193. [DOI] [PubMed] [Google Scholar]
  11. Rolston K. V., Haron E., Cunningham C., Bodey G. P. Intravenous ciprofloxacin for infections in cancer patients. Am J Med. 1989 Nov 30;87(5A):261S–265S. doi: 10.1016/0002-9343(89)90076-4. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES